SYMNET: A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea

Sponsor
Ipsen (Industry)
Overall Status
Completed
CT.gov ID
NCT01234168
Collaborator
(none)
340
57
26
6
0.2

Study Details

Study Description

Brief Summary

The purpose of the protocol is to to assess subject's overall satisfaction regarding control of diarrhea. The study aims to supplement results obtained through clinical trials with data obtained from a population of patients receiving treatment with Somatuline Autogel in routine practice.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    340 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    An International, Cross Sectional, Non-interventional, Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
    Study Start Date :
    Oct 1, 2010
    Actual Primary Completion Date :
    Dec 1, 2012
    Actual Study Completion Date :
    Dec 1, 2012

    Outcome Measures

    Primary Outcome Measures

    1. Subject's overall satisfaction regarding control of diarrhea [Day of survey]

      Use of questionnaires to assess patient satisfaction (Likert scale).

    Secondary Outcome Measures

    1. Impact on daily activities of the clinical manifestations of diarrhea [Day of survey]

      Use of questionnaires to assess symptom severity and impact on patient's daily activities (CGI-S).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Out-patients 18 years of age and older, who have agreed to participate in the study

    • Diagnosed with a Neuroendocrine tumour (NET) and receiving treatment with Somatuline Autogel

    Exclusion Criteria:
    • Subjects for whom there are reasons that may hinder the conduct of the study (patients who have difficulty expressing themselves or who are unable to complete the questionnaires, or with insufficient data in the their files will not be enrolled in the study).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Teaching Hospital Brno Bohunice Brno Czechia
    2 University Hospital Hradec Kralove Hradec Kralove Czechia
    3 Hospital Pardubice Pardubice Czechia
    4 Teaching Hospital Plzen Czechia
    5 Charles University Praha Czechia
    6 Teaching Hospital Na Bulovce Praha Czechia
    7 CHU Angers Angers France 49933
    8 Hôpital Avicenne Bobigny France 93009
    9 Hôpital Saint André Bordeaux France 33075
    10 CHU Trousseau Chambray Les Tours France 37171
    11 Hôpital Beaujon Clichy France 92118
    12 CHU Michallon Grenoble France 38043
    13 Hôpital Edouard Herriot Lyon France 69437
    14 CHU Timone Marseille France 13385
    15 Hôpital Archet 2 Nice France 06202
    16 Hôpital du Haut Leveque Pessac France 33604
    17 Hôpital Robert Debré Reims France 51092
    18 CHU St Etienne Saint Priest France 42270
    19 Hôpital Rangueil Toulouse France 31059
    20 Institut Gustave-Roussy Villejuif France 94805
    21 Semmelweis University Budapest Hungary 1088
    22 Karádi-Nagy Bt. Pécs Hungary 7624
    23 Hadasit Medical Research Jerusalem Israel
    24 Ospedale Regina Apostolorum Albano Laziale Italy
    25 Ospedale Pesenti Fenaroli Alzano Lombardo Italy
    26 Ospedale Civile Castelfranco Veneto Italy
    27 Università degli Studi di Chieti Chieti Italy
    28 Istituti Ospedalieri di Cremona Cremona Italy
    29 Azienda Ospedaliera-Universitaria Policlinico Modena Italy
    30 U.O.C. Malattie dell'Apparato Digerente e del Fegato Roma Italy
    31 Unità di Endocrinologia Istituti Fisioterapici Ospitalieri Roma Italy
    32 Casa Sollievo della Sofferenza San Giovanni Rotondo Italy
    33 Istituto Oncologico del Mediterraneo Viagrande Italy
    34 Szpital Uniwersytecki im. A. Jurasza Bydgoszcz Poland
    35 Slaskiego Uniwersytetu Medycznego Katowice Poland
    36 Szpital Uniwersytecki w Krakowie Krakow Poland
    37 Szpital Uniwersytecki w Lodzi Lodz Poland
    38 Prywatna Praktyka Lekarska Olsztyn Poland
    39 Specjalistyczny Gabinet Lekarski Poznan Poland
    40 Samodzielny Publiczny Szpital Kliniczny Nr 1 Szczecin Poland
    41 Niepubliczny Zaklad Opieki Zdrowotnej Warszawa Poland
    42 Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie Warszawa Poland
    43 Wojskowy Instytut Medyczny Warszawa Poland
    44 Hospital De Cruces Barakaldo Spain
    45 Hospital Universitari de Bellvitge Barcelona Spain
    46 Hospital General Reina Sofia Cordoba Spain
    47 Hospital Clinico Universitario de Santiago La Coruña Spain
    48 Hospital Clinico San Carlos Madrid Spain
    49 Hospital Xeral Cies de Vigo Pontevedra Spain
    50 Hospital Virgen Macarena Sevilla Spain
    51 Hospital Universitario Miguel Servet Zaragoza Spain
    52 University Hospital of Wales Cardiff United Kingdom CF14 4XN
    53 University Hospital Coventry United Kingdom CV2 2DX
    54 University Hospital Aintree Liverpool United Kingdom L9 7AL
    55 Royal Free Hospital London United Kingdom
    56 Chrisite Hospital Institute Manchester United Kingdom M204BX
    57 Freeman Hospital Newcastle upon Tyne United Kingdom NE7 7DN

    Sponsors and Collaborators

    • Ipsen

    Investigators

    • Study Director: Ipsen Study Director, Ipsen

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ipsen
    ClinicalTrials.gov Identifier:
    NCT01234168
    Other Study ID Numbers:
    • 8-79-52030-736
    First Posted:
    Nov 4, 2010
    Last Update Posted:
    Nov 5, 2020
    Last Verified:
    Nov 1, 2020

    Study Results

    No Results Posted as of Nov 5, 2020